Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Psilocybin × Other neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Other neoplasm 1 Lymphoid 1 Dermatologic 1

Conditions

Interventions

Cyclophosphamide 7 fludarabine phosphate 6 Peripheral Blood Stem Cell Transplantation 6 Whole-Body Irradiation 5 Tacrolimus 4 Mycophenolic Acid 4 Methotrexate 4 Melphalan 4 Busulfan 4 Sulindac 3 Paclitaxel 3 Cyclosporine 3 Cisplatin 3 Capecitabine 3 Antilymphocyte Serum 3 toripalimab 2 sintilimab 2 fludarabine 2 Taxes 2 Surveys and Questionnaires 2 Specimen Handling 2 Sirolimus 2 Radiotherapy 2 Patient Reported Outcome Measures 2 Nivolumab 2 Mesna 2 Magnetic Resonance Spectroscopy 2 Hyperthermic Intraperitoneal Chemotherapy 2 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2 Gene Expression Profiling 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04950608 2026-02-17

PATH

Dana-Farber Cancer Institute

Phase 2 Completed

15 enrolled 26 charts

Hospice

Data powered by HemOnc (CC BY 4.0) Colophon ⚡